Default company panoramic image
Logo

Lenimen

Translating biomarker discoveries into novel diagnostics and therapeutics for Chronic Obstructive Pulmonary Disease (COPD). The biomarkers have been identified.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Denver, CO, USA
  • Currency USD
  • Founded March 2012
  • Employees 4
  • Website Lenimen.com

Company Summary

Lenimen's intellectual property is set to change the standard of care as is relates to risk stratification and pharmacological therapies in COPD. Recent legislative changes have exposed U.S. hospitals to a billion dollars in direct penalties and over $1.3 billion in uncompensated care due to hospital readmissions. Lenimen’s near term market opportunity is estimated at $250M annually thru the reduction in hospital readmission rates for COPD.

Team

  • Default avatar
    Russell P. Bowler
    Co-founder and Chief Medical Officer

    Dr. Bowler earned his bachelor’s degree in Mathematics and Computational Sciences at Stanford University in 1988. He obtained his M.D. with thesis at the University of California at San Francisco (UCSF) in 1993 and did his thesis work in the Nobel Laureate Lab of Stan Prusiner. His internal medicine residency was also at UCSF and his pulmonary and critical care fellowship at the University of Colorado. He obtained his Ph.D. in Cell and Developmen

  • 0680a563 2bc4 4f2a 8dc4 ac1994307967
    Co-founder and Chief Scientific Officer

    Dr. Raul Torres earned his Ph.D. at the University of Washington in the field of immunology and in the laboratory of Ed Clark, Ph.D. He continued his immunology training in Cologne, Germany at the Institute for Genetics, University of Cologne under Professor Klaus Rajewsky, a European dean of immunology. Dr. Torres subsequently held the position of Scientific Member at the prestigious Basel Institute for Immunology in Basel Switzerland where he i

  • 69cff890 b6b0 4276 a6df fa6c98ad7bdc
    Chief Executive Officer

    As the Chief Executive Officer and member of the Board of Directors, Brett oversees all business activities including development, strategy, and revenue, as well as partnerships.
    Prior to joining Lenimen, he led Walgreen’s US sales, business development, and strategic initiatives in the Hospital and Health Systems segment, focused on the transition of care and development of integrated collaborative healthcare delivery systems.

  • 56bd5e0f 9722 460b 8ad0 b21acd7201c0
    Chief Business Officer

    Mr. Hankins is a pharmaceutical and biotechnology business professional with 20+ years of experience in the industry. As Chief Business Officer he is responsible for IP and business development. Mr. Hankins has held senior management positions with Cardinal Health, CIMA Labs, Sanofi-Pasteur, and the National Institutes of Health. He is a registered US Patent Attorney, a Certified Licensing Professional, and a member of the Georgia bar.

Advisors

  • Default avatar
    Michael Weiner
    Lawyer
    Unconfirmed